Status:
UNKNOWN
A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients
Lead Sponsor:
Korean Gynecologic Oncology Group
Conditions:
Endometrial Cancer
Eligibility:
FEMALE
20-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether post-operative concurrent chemoradiation with paclitaxel is effective and safe in the treatment of high risk postoperative endometrial cancer patients...
Detailed Description
Postoperative radiotherapy (RT) is the most used adjuvant treatment in high risk endometrial cancer (HREC), and it appears to reduce the incidence of pelvic relapses but doesn't seem to improve surviv...
Eligibility Criteria
Inclusion
- Patients undertaken total hysterectomy, bilateral salpingoophorectomy, washing cytology, pelvic and paraaortic lymph node dissection
- Patients must have the diagnosis of endometrioid type adenocarcinoma with stage III, IV.
- Patients must have a GOG performance of 0, 1, or 2.
- Patients must have expected life span over 6 months.
Exclusion
- Patients with peripheral neurotoxicity over grade 2 in CTC criteria.
- Patients with history of chemotherapy or radiation treatment.
- patients with history of arrhythmia,congestive heart failure.
- Patients with intractable infection.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00373620
Start Date
January 1 2006
Last Update
September 8 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Young-Dong Severance Hospital
Seoul, South Korea, 135-720